Characterization of moclobemide N-oxidation in human liver microsomes

References

• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• BRUNELLE, A., BI, Y. A., LIN, J., RUSSELL, B., LUY, L., BERKMAN, C. and CASHMAN, J., 1997, Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherkhia coli as maltose binding protein fusions. Drug Metabolism and Disposition, 25, 1001–1007.
   PubMed Web of Science ®Google Scholar
• CASHMAN, J., 1999, In T. F. Woolf (ed.), Handbook of Drug Metabolism (New York: Dekker), pp. 477–505.
   Google Scholar
• CASHMAN, J. R., AKERMAN, B. R., FORREST, S. M. and TREACY, E. P., 2000, Population-specific polymorphisms of the human FM03 gene: significance for detoxication. Drug Metabolism and Disposition, 28, 169-1 73.
   Google Scholar
• CASHMAN, J. R., YANG, Z., YANG, L. and WRIGHTON, S. A., 1993, Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metabolism and Disposition, 21, 492–501.
   PubMed Web of Science ®Google Scholar
• CHANG, T. K., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   PubMed Web of Science ®Google Scholar
• CHIBA, K., MANABE, K., KOBAYASHI, K., TAKAYAMA, Y., TANI, M. and ISHIZAKI, T., 1993, Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes. European Journal of Clinical Pharmacology, 44, 559–562.
   PubMed Web of Science ®Google Scholar
• DA PRADA, M., KETTLER, R., KELLER, H. H., BURKARD, W. P., MUGGLI-MANIGLIO, D. and HAEFELY, W. E., 1989, Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 400–414.
   Google Scholar
• DOLPHIN, C. T., JANMOHAMED, A., SMITH, R. L., SHEPHARD, E. A. and PHILLIPS, I. R., 1997, Missense mutation in flavin- containing mono-oxygenase 3 gene, FM03, underlies fish-odour syndrome. Nature Genetics, 17, 491–494.
   PubMed Web of Science ®Google Scholar
• GESCHKE, R., KORNER, J. and EGGERS, H., 1987, Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. Journal of Chromatography, 420, 111–120.
   PubMed Web of Science ®Google Scholar
• GRAM, L. F., GUENTERT, T. W., GRANGE, S., VISTISEN, K. and BROSEN, K., 1995, Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clinical Pharmacology and Therapeutics, 57, 670–677.
   PubMed Web of Science ®Google Scholar
• GROTHUSEN, A., HARDT, J., BRAUTIGAM, L., LANG, D. and BUCKE R., 1996, A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes. Archives of Toxicology, 71, 64–71.
   PubMed Web of Science ®Google Scholar
• JAUCH, R., GRIESSER, E., OESTERHELT, G., ARNOLD, W., MEISTER, W., ZIEGLER, W. H. and GUENTERT, T. W., 1990, Biotransformation of moclobemide in humans. Acta Psychiatrica Scandinavica, Supplementum, 360, 87–90.
   Google Scholar
• KANG, J. H., CHUNG, W. G., LEE, K. H., PARK, C. S., KANG, J. S., SHIN, I. C., ROH, H. K., DONG, M. S., BAEK, H. M. and CHA, Y. N., 2000, Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. Pharmacogenetics, 10, 67–78.
   PubMedGoogle Scholar
• KERRY, N. L., SOMOGYI, A. A., Mixus, G. and BOCHNER, F., 1993, Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochemical Pharmacology, 45, 833–839.
   PubMed Web of Science ®Google Scholar
• LANG, D. H. and RETTIE, A. E., 2000, In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. British Journal of Clinical Pharmacology, 50, 311–314.
   PubMed Web of Science ®Google Scholar
• LANG, D. H., YEUNG, C. K., PETER, R. M., IBARRA, C., GASSER, R., ITAGAKI, K., PHILPOT, R. M. and RETTIE, A. E., 1998, Isoforrn specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FM03. Biochemical Pharmacology, 56, 1005–1012.
   PubMed Web of Science ®Google Scholar
• LEMOINE, A., JOHANN, M. and CRESTEIL, T., 1990, Evidence for the presence of distinct flavin-containing monooxygenases in human tissues. Archives of Biochemistry and Biophysics, 276, 336–342.
   PubMedGoogle Scholar
• MAYERSOHN, M. and GUENTERT, T. W., 1995, Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clinical Pharmacokinetks, 29, 292–332.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P45 Os: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• OVERBY, L. H., CARVER, G. C. and PHILPOT, R. M., 1997, Quantitation and kinetic properties of hepatic microsomal and recombinant fiavin- containing monooxygenases 3 and 5 from humans. Chemko-Biological Interactions, 106, 29–45.
   PubMed Web of Science ®Google Scholar
• RIEUTORD, A., STUPANS, I., SHENFIELD, G. M. and GROSS, A. S., 1995, Gliclazide hydroxylation by rat liver microsomes. Xenobiotica, 25, 1345–1354.
   PubMed Web of Science ®Google Scholar
• RING, B. J., CATLOW, J., LINDSAY, T. J., GILLESPIE, T., ROSKOS, L. K., CERIMELE, B. J., SWANSON, S. P., HAMMAN, M. A. and WRIGHTON, S. A., 1996, Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. journal of Pharmacology and Experimental Therapeutics, 276, 658–666.
   PubMed Web of Science ®Google Scholar
• SADEQUE, A. J., THUMMEL, K. E. and RETTIE, A. E., 1993, Purification of macaque liver fiavin-containing monooxygenase: a form of the enzyme related immunochemically to an isozyme expressed selectively in adult human liver. Biochimica et Biophyska Acta, 1162, 127–134.
   PubMed Web of Science ®Google Scholar
• SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294–300.
   PubMed Web of Science ®Google Scholar
• TUGNAIT, M., HAWES, E. M., McKAv, G., RETTIE, A. E., HAINING, R. L. and MIDHA, K. K., 1997, N-oxygenation of clozapine by fiavin-containing monooxygenase. Drug Metabolism and Disposition, 25, 524–527.
   PubMed Web of Science ®Google Scholar
• ZSCHOCKE, J., KOHLMUELLER, D., QUAK, E., MEISSNER, T., HOFFMANN, G. F. and MAYATEPEK, E., 1999, Mild trirnethylaminuria caused by common variants in FM03 gene. Lancet, 354, 834–835.
   PubMed Web of Science ®Google Scholar